BioLamina, a leading provider of biologically relevant matrix proteins for stem cell culture, today announced a strategic collaboration with Axion BioSystems, a leader in next-generation live-cell analysis technologies.

Axion BioSystems will incorporate BioLamina’s full-length, human recombinant Biolaminin 332 LN (LN332), into a new offering designed to support the improved neural and cardiac organoid attachment to multielectrode array (MEA) plates.

“Pairing our Biolaminin technology with Axion BioSystems MEA plates allows researchers to quantitatively measure organoid function. We are thrilled to work with the team at Axion BioSystems to enable our partners to capture more meaningful data from complex models.”

Dr Therése Kallur, Chief Scientific & Business Development Officer at BioLamina

In Axion’s internal testing, Biolaminin 332 LN (LN332) supported sustained organoid attachment to 3DMap MEAs during long-term experiments, consistent with laminin-332’s established role in cell adhesion. Together, the new offering simplifies organoid preparation for MEA studies.

“Organoid research is advancing quickly, and the tools surrounding these models must evolve alongside it. By bringing together BioLamina’s solutions for improved organoid attachment with Axion’s functional analysis technologies, this partnership helps researchers gain more meaningful data from increasingly complex models.”

Dr Stacie Chvatal, Vice president of Product Management at Axion BioSystems

This new collaboration reflects a shared scientific commitment to creating the optimal cellular microenvironment for organoid attachment, enabling more robust functional analysis and advancing reproducible, scalable organoid workflows for disease modeling and therapeutic discovery.

The companies will jointly support the launch through coordinated marketing activities, scientific engagement, and conference collaborations throughout 2026. 

Background

About BioLamina 

BioLamina is a biotechnology company with deep expertise in matrix biology and cell culture. The company develops and manufactures laminin-based cell culture substrates that enable reliable growth and differentiation of pluripotent stem cells and other primary cells. 

By providing defined, high-quality and scalable cell culture solutions, BioLamina supports researchers and developers in advancing cell therapies and improving the accuracy of cell-based models used in drug discovery and development. 

Biolaminin® substrates are full-length, chemically defined and animal origin-free human recombinant laminins, designed for controlled cell culture systems and used in cell therapy development, including phase I–III clinical trials across major regulatory jurisdictions. BioLamina is headquartered in Stockholm, Sweden. 

About Axion BioSystems

Axion BioSystems is a leading life sciences tools company focused on innovative live-cell assays used to study the function of cells in vitro for drug discovery and disease modeling. The team at Axion BioSystems is dedicated to continuing the advancement of new technologies that accelerate research and further the understanding of biological complexity outside of the body. Axion BioSystems is headquartered in Atlanta, Georgia, USA, and has offices worldwide. 

Press contacts:  

BioLamina: Sandra Falci, Interim Marketing Manager | sandra.falci@biolamina.com    

Axion BioSystems: Victoria Stahl, VP Marketing | vstahl@axionbio.com